Mork Capital Management’s United Therapeutics UTHR Stock Holding History

Mork Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.22M	Hold	4,100	–	–	1.42%	18
2026 Q1	$2.43M	Hold	4,100	–	–	1.73%	10
2025 Q4	$2M	Hold	4,100	–	–	1.22%	17
2025 Q3	$1.72M	Hold	4,100	–	–	1.18%	22
2025 Q2	$1.18M	Hold	4,100	–	–	0.86%	46
2025 Q1	$1.26M	Hold	4,100	–	–	0.99%	29
2024 Q4	$1.45M	Hold	4,100	–	–	0.95%	30
2024 Q3	$1.47M	Hold	4,100	–	–	1.05%	31
2024 Q2	$1.31M	Hold	4,100	–	–	1.02%	31
2024 Q1	$942K	Hold	4,100	–	–	0.71%	88
2023 Q4	$902K	Hold	4,100	–	–	0.55%	110
2023 Q3	$926K	Hold	4,100	–	–	0.72%	59
2023 Q2	$905K	Hold	4,100	–	–	0.69%	65
2023 Q1	$918K	Hold	4,100	–	–	0.75%	58
2022 Q4	$1.14M	Hold	4,100	–	–	0.87%	37
2022 Q3	$858K	Hold	4,100	–	–	0.84%	54
2022 Q2	$966K	Hold	4,100	–	–	0.88%	49
2022 Q1	$736K	Hold	4,100	–	–	0.66%	90
2021 Q4	$886K	Hold	4,100	–	–	0.6%	101
2021 Q3	$757K	Hold	4,100	–	–	0.65%	85
2021 Q2	$736K	Hold	4,100	–	–	0.53%	87
2021 Q1	$686K	Hold	4,100	–	–	0.52%	86
2020 Q4	$622K	Hold	4,100	–	–	0.46%	98
2020 Q3	$414K	Hold	4,100	–	–	0.45%	86
2020 Q2	$496K	Hold	4,100	–	–	0.58%	84
2020 Q1	$389K	Hold	4,100	–	–	0.53%	88
2019 Q4	$361K	Hold	4,100	–	–	0.26%	119
2019 Q3	$327K	Hold	4,100	–	–	0.3%	105
2019 Q2	$320K	Hold	4,100	–	–	0.3%	100
2019 Q1	$481K	Hold	4,100	–	–	0.45%	100
2018 Q4	$446K	Hold	4,100	–	–	0.42%	110
2018 Q3	$524K	Hold	4,100	–	–	0.42%	101
2018 Q2	$464K	Hold	4,100	–	–	0.41%	98
2018 Q1	$461K	Hold	4,100	–	–	0.44%	97
2017 Q4	$607K	Hold	4,100	–	–	0.41%	121
2017 Q3	$480K	Hold	4,100	–	–	0.39%	108
2017 Q2	$532K	Hold	4,100	–	–	0.46%	106
2017 Q1	$555K	Hold	4,100	–	–	0.49%	107
2016 Q4	$588K	Hold	4,100	–	–	0.41%	132
2016 Q3	$484K	Hold	4,100	–	–	0.46%	104
2016 Q2	$434K	Sell	4,100 -4,000	-49%	-$446K	0.43%	108
2016 Q1	$903K	Buy	8,100 +2,100	+35%	+$266K	0.88%	38
2015 Q4	$940K	Hold	6,000	–	–	0.9%	31
2015 Q3	$787K	Hold	6,000	–	–	0.93%	40
2015 Q2	$1.04M	Hold	6,000	–	–	1.23%	15
2015 Q1	$1.03M	Sell	6,000 -4,000	-40%	-$610K	1.2%	16
2014 Q4	$1.29M	Buy	+10,000	New	+$1.29M	0.99%	6

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Mork Capital Management's UTHR Position: Q2 2026 in Review

Mork Capital Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 4,100 shares worth $2.22M. The position accounts for 1.42% of the portfolio, ranked #18.

Mork Capital Management first reported a position in UTHR in Q4 2014 and has held it in 47 quarters since. The position peaked at $2.43M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Mork Capital Management held 4,100 shares of United Therapeutics worth $2.22M as of Q2 2026.
Mork Capital Management left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up 1.42% of Mork Capital Management's portfolio in Q2 2026, its #18 holding.
Mork Capital Management first reported a position in United Therapeutics in Q4 2014 and has held it in 47 quarters since.
Mork Capital Management's United Therapeutics position peaked at $2.43M in Q1 2026.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Mork Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.